Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

With CIPLA's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 4.239000
forwardPE 22.580973
debtToEquity 1.400000
earningsGrowth 0.301000
revenueGrowth 0.069000
grossMargins 0.671070
operatingMargins 0.186260
trailingEps 65.260000
forwardEps 63.540000

Cipla Limited's current ratio of 4.239 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring Cipla Limited is unlikely to face difficulties in meeting immediate financial obligations.
Cipla Limited's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
CIPLA's forward EPS being lower than its trailing EPS suggests that the company's earnings may decline in the current year. This could indicate financial challenges ahead for the company.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

Price projections for CIPLA have consistently been revised upward, indicating positive sentiment toward the company. This gradual adjustment reflects growing confidence in CIPLA's future potential and financial outlook among analysts.

Insider Transactions:

Insider Transactions for CIPLA
Insider Transactions for CIPLA


2 sales of CIPLA stock were made, with market price at 1590.4249877929688 per share.No sell transactions occurred during the period under consideration.Investors are purchasing CIPLA more frequently than selling it near the current price levels, which might point to a bullish sentiment. This pattern could be interpreted as a favorable outlook for the stock's future.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


A recent buy bias from analysts toward CIPLA indicates strong confidence in the stock's future performance. This could encourage investors to park their money in CIPLA, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.